Recombinant Human SMYD3 Protein

Name: Recombinant Human SMYD3 Protein
Brand: Beta LifeScience
SKU: BL-0217SG
Availability: InStock

Collections: Other recombinant proteins, Recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Tag	GST
Host Species	Human
Accession	BC031010
Synonym	ZMYND1; ZNFN3A1; FLJ21080
Background	SMYD3 (SET and MYND domain containing 3) is a histone methyltransferase that plays a role in transcriptional regulation as a member of an RNA polymerase complex. The introduction of SMYD3 enhanced cell growth and the histone methyltransferase activity of SMYD3 involved in the proliferation of cancer cells (1). A variable number of tandems repeat polymorphism in an E2F-1 binding element in the 5-prime flanking region of SMYD3 is a risk factor for human cancers (2).
Description	Recombinant full-length human SMYD3 was produced by baculovirus in Sf9 insect cells, fused with a GST tag at N-terminus. This protein is purified with our unique purification methods.
Source	Sf9 insect cells
AA Sequence	Full Length
Molecular Weight	71 kDa
Purity	For specific purity information on a given lot, see related COA.
Endotoxin	< 1.0 EU per μg of the protein as determined by the LAL method
Bioactivity	Active
Formulation	Recombinant protein is supplied in 50mM Tris-HCl, pH 7.5, 50mM NaCl, 10mM Glutathione, 0.25mM DTT, 0.1mM EDTA, 0.1mM PMSF and 25% glycerol.
Stability	The recombinant protein is stable for up to 12 months at -70°C
Usage	For Research Use Only
Storage	Recombinant Human SMYD3 Protein should be stored should be stored at < -70°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

Target Details

Target Function	Histone methyltransferase. Specifically methylates 'Lys-4' of histone H3, inducing di- and tri-methylation, but not monomethylation. Also methylates 'Lys-5' of histone H4. Plays an important role in transcriptional activation as a member of an RNA polymerase complex. Binds DNA containing 5'-CCCTCC-3' or 5'-GAGGGG-3' sequences.
Subcellular Location	Cytoplasm. Nucleus.
Protein Families	Class V-like SAM-binding methyltransferase superfamily, Histone-lysine methyltransferase family
Database References	HGNC: 15513 OMIM: 608783 KEGG: hsa:64754 STRING: 9606.ENSP00000373637 UniGene: Hs.567571
Tissue Specificity	Expressed in skeletal muscles and testis. Overexpressed in a majority of colorectal and hepatocellular carcinomas.

Gene Functions References

Study reported for the first time that SMYD3 promoter hypomethylation was associated with colorectal cancer in a Chinese cohort. PMID: 29969917
The property that SMYD3 is preferentially recruited to individual promoters may rely on both its binding sequences and its binding partners. Further investigation is required to clarify this specificity. PMID: 28630472
High Ki67, EZH2, and SMYD3 immunoexpression, adjusted for standard clinicopathological parameters, independently predicts outcome in patients with prostate cancer, at diagnosis. PMID: 29174711
SMYD3 VNTR 3/3 polymorphism confers an increased risk and poor prognosis of hepatocellular carcinoma in a Chinese population PMID: 29691085
EZH2 rs12670401 and rs6464926 polymorphisms, EZH2 and SMYD3 expression, clinical staging, lymph node metastasis, human epidermal growth factor receptor-2 (HER2) status, and metastasis may be correlated with breast cancer susceptibility and prognosis. PMID: 29089464
Overexpression of SMYD3 is an independent prognostic risk of unfavorable prognosis of hepatocellular carcinoma (HCC). The anti-SMYD3 therapy may be a potential approach to treat HCC. PMID: 29187705
SMYD3-mediated methylation of HER2 at Lysine 175 may regulate the formation of HER2 homodimer and subsequent autophosphorylation and suggest that the SMYD3-mediated methylation pathway seems to be a good target for development of novel anti-cancer therapy. PMID: 28639750
SMYD3-mediated methylation of AKT1 at lysine 14 is essential for AKT1 activation and that SMYD3-mediated AKT1 methylation appears to be a good target for development of anti-cancer therapy. PMID: 27626683
However, stratification of patients according to their smoking history significantly expands the prognostic value of SMYD3 to overall survival and other features, suggesting that smoking-related effects saturate the clinical analysis and mask the function of SMYD3 as an oncogenic potentiato PMID: 27554136
SMYD3 enhances tumorigenicity in esophageal squamous cell carcinoma by enhancing transcription of ezrin and LOXL2, which are involved in proliferation, migration, and invasion. PMID: 26980013
SMYD3-mediated H2A.Z.1K101 dimethylation activates cyclin A1 expression and contributes to driving the proliferation of breast cancer cells. PMID: 27569210
VNTR genotype 3/3 of the SMYD3 gene was associated with the risk of ovarian cancer. PMID: 28024138
The present results suggest that NS5A interacts with SMYD3 and induces AP-1 activation, possibly by facilitating binding between HSP90 and SMYD3. This may be a novel mechanism of AP-1 activation in HCV-infected cells. PMID: 27080060
SMYD3 physically interacts with the promoter of BCLAF1 and upregulates its expression by accumulating di- and trimethylation of H3K4 at the BCLAF1 locus. SMYD3 overexpression in bladder cancer cells promotes autophagy activation. PMID: 26676636
High expression of SMYD3 is associated with chronic lymphocytic leukemia. PMID: 26790435
results clearly revealed structural determinants for the substrate preference of SMYD3 and provided mechanistic insights into lysine methylation of MAP3K2. PMID: 26929412
A novel HBx-interacting protein, SMYD3, was identified, leading to proposal of a novel mechanism of AP-1 activation in HBV-infected cells. PMID: 26616333
Postulate that AdoMet cofactor acts like a key and locks Smyd3 in a closed conformation. PMID: 27085704
Results showed that SMYD3 is overexpressed in human glioma and contributes to glioma tumorigenicity through p53. PMID: 26328527
SMYD3 interacts with the human positive coactivator 4 (PC4) and that such interaction potentiates a group of genes whose expression is linked to cell proliferation and invasion. PMID: 26350217
Results support a proto-oncogenic role for SMYD3 in prostate carcinogenesis, mainly due to its methyltransferase enzymatic activity. PMID: 25980436
role of histone methyltransferase SMYD3 in tumors PMID: 25248712
Loss of SMYD3-HSP90 interaction leads to SMYD3 mislocalization within the nucleus, thereby losing its chromatin association. This results in reduction of SMYD3-mediated cell proliferation and, potentially, impairment of SMYD3's oncogenic activity. PMID: 25738358
High SMYD3 and pSTAT3 expressions may indicate poor prognosis of patients with gastric cancer PMID: 25471787
Results suggest that high expression of SMYD3 is related to the occurrence of esophageal squamous cell carcinoma. Also, its suppression promoted the expression of RIZ1 suggesting a signal transduction pathway between SMYD3 and RIZ1. PMID: 24993551
SMYD3 and MMP-9 may play important roles in tumor invasion, metastasis, and prognosis and could work as promising targets for prognostic prediction in gastric cancer. PMID: 25627005
SET and MYND domain-containing protein 3 expression and TGF-beta1 expression in gastric cancer (GC) tissues were significantly and positively correlated. High expression levels of SMYD3 and TGF-beta1 can indicate poor prognoses for GC patients. PMID: 26077602
represent the proof of principle that SMYD3 is a druggable target PMID: 25728514
SMYD3-mediated methylation of MAP3K2 increases mutant K-Ras-induced activation of ERK1/2. (Review) PMID: 25382779
SMYD3 performed an important function in the aggressiveness of gastric carcinoma and may act as a promising target for prognostic prediction. PMID: 25472580
The expression profiling revealed in the more aggressive diseases (i.e. occurrence of metastases; persistent disease; disease-related death) a significant increase of EZH2 and SMYD3 gene expression. PMID: 24813658
Mutational analyses revealed that the MYND-domain of SMYD3 and domain III of hepatitis C virus NS5A are required for the interaction. PMID: 25092459
methylation of MAP3K2 by SMYD3 increases MAP kinase signalling and promotes the formation of Ras-driven carcinomas PMID: 24847881
SMYD3 promotes prostate tumorigenesis and mediates epigenetic upregulation of AR expression. PMID: 24174655
low miR-124 levels mediated by HCV core protein via DNMT1 promote intrahepatic cholangiocarcinoma cell migration and invasion by targeting SMYD3 PMID: 22819820
Depletion of Smyd3 leads to diminished cell proliferation in HeLa cell line. PMID: 22419068
Down-regulation of SMYD3 induces G1-phase cell cycle arrest, indicating the potent induction of apoptosis by SMYD3 knockdown. PMID: 20957523
Results show SMYD3 as an important new regulator of MMP-9 transcription, and provide a molecular link between SMYD3 overexpression and metastatic cancer progression. PMID: 22194464
The structure revealed an overall compact architecture in which the "split-SET" domain adopts a canonical SET domain fold and closely assembles with a Zn-binding MYND domain and a C-terminal superhelical 9 alpha-helical bundle. PMID: 21779408
HCVc could upregulate the methylation status of the RASSF1A promoter through regulation of SMYD3, and histone methylation may affect the DNA methylation of downstream gene by an unknown mechanism PMID: 21450690
Structural analysis shows that the previously uncharacterized C-terminal domain of Smyd3 contains a tetratrico-peptide repeat domain which together with the SET and post-SET domains forms a deep, narrow substrate binding pocket. PMID: 21266482
SmyD3 has a two-lobed structure with the substrate binding cleft located at the bottom of a 15-A-deep crevice formed between the N- and C-terminal lobes. PMID: 21167177
presence of activating KRAS mutations is significantly correlated to an upregulation of 13 genes (adjusted P-value <0.05), among them DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase PMID: 20725992
HBx may induce the expression of histone methyltransferase SMYD3, which in turn stimulates cell proliferation and blocks apoptosis in HepG2 cells. PMID: 19403031
SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. PMID: 15235609
SMYD3-NY is a novel transcript variant of the SMYD3 gene, and SMYD3-NY protein may influence transcriptional regulation during spermatogenesis via HTMase activity PMID: 16081583
The common variable number of tandem repeats polymorphism in SMYD3 is a susceptibility factor for some types of human cancer. PMID: 16155568
Enhanced SMYD3 expression is associated with growth of breast cancer PMID: 16441421
study shows that SMYD3 polymorphism is not associated with the occurrence and metastasis of hepatocellular carcinoma in Chinese population PMID: 17431393
The proliferation, migration induction and apoptosis inhibition activities of SMYD3 in hepatocellular carcinoma may be mediated through RIZ1 CpG promoter hypermethylation. PMID: 17963297

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.